Potential therapeutic implications of EGF R/PDGF R signalling pathways in bone metastases of prostate cancer;Les voies de signalisation EGF R/PDGF R dans les métastases osseuses du cancer de prostate: Leurs implications thérapeutiques potentielles

Progres en Urologie

Volumn 15, Issue 4, 2005, Pages 616-620

  Paule, Bernard ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Bone metastases; EGF R HER2 inhibitors; PDGF R antagonists; Prostate cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR;

ANIMAL; BONE TUMOR; DRUG ANTAGONISM; HUMAN; MALE; METASTASIS; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BONE NEOPLASMS; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 27644570087     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. ABREU-MARTIN M.T., CHARI A., PALLADINO A.A., CRAFT N.A., SAWYERS C.L. : Mitogen activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol. Cell. Biol., 1999 ; 19 : 5143-5154.
2. AGUS D.B., BUNN P.A. JR, FRANKLIN W., GARCIA M., OZOLS R.F. : HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin. Oncol., 2000 ; 27 : 53-63.
3. APTE S.M., FAN D., KILLION J.J., FIDLER I.J. : Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin. Cancer Res., 2004 ; 10 : 897-908.
4. BLACKLEDGE G. : Growth factor receptor tyrosine kinase inhibitors : clinical development and potential for prostate cancer therapy. J. Urol., 2003 ; 170 : S77-S83.
5. CALVO B.F., LEVINE A.M., MARCOS M., COLLINS Q.F., IACOCCA M.V., CASKEY L.S., GREGORY C.W., LIN Y., WHANG Y.E., EARP H.S., MOHLER J.L. : Human epidermal receptor-2 expression in prostate cancer. Clin. Cancer Res., 2003 ; 9 : 1087-1097.
6. CRAFT N., SHOSTAK Y., CAREY M., AND SAWYERS C.L. : A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med., 1999 ; 5 : 280-285.
7. CUNNINGHAM D., HUMBLET Y., SIENA S., KHAYAT D., BLEIBERG H., SANTORO A., BETS D., MUESER M., HARSTRICK A., VERSLYPE C., CHAU I., VAN CUTSEM E. : Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med., 2004 ; 351 : 337-345.
8. DI LORENZO G., TORTORA G., D'ARMIENTO F.P., DE ROSA G., STAIBANO S., AUTORINO R., D'ARMIENTO M., DE LAURENTIIS M., DE PLACIDO S., CATALANO G., BIANCO A.R., CIARDIELLO F. : Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin. Cancer Res., 2002 ; 8 : 3438-3444.
9. FIDLER I.J. : Modulation of the organ microenvironment for treatment of cancer metastasis. J. Natl. Cancer Inst., 1995 ; 87 : 1588-1592.
10. GRIFFON-ETIENNE G., BOUCHER Y., BREKKEN C., SUIT H.D., AND JAIN R.K. : Taxane induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res., 1999 ; 59 : 3776-3782.
11. HEUCHEL R., BERG A., TALLQUIST M., AHLEN K., REED R.K., RUBIN K., CLAESSONWELSH L., HELDIN C.H., AND SORIANO P. : Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3 kinase signaling. Proc. Natl. Acad. Sci. USA, 1999 ; 96 : 11410-11415.
12. HWANG R.F., YOKOI K., BUCANA C.D., TSAN R., KILLION J.J., EVANS D.B., FIDLER I.J. : Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin. Cancer Res., 2003 ; 9 : 6534-6544.
13. KIM S.J., UEHARA H., KARASHIMA T., SHEPHERD D.L., KILLION J.J., FIDLER I.J. : Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin. Cancer Res., 2003 ; 9 : 1200-1210.
14. KO Y.J., SMALL E.J., KABBINAVAR F., CHACHOUA A., TANEJA S., REESE D., DEPAOLI A., HANNAH A., BALK S.P., BUBLEY G.J. : A multiinstitutional phase II study of SU101 a platelet derived growth factor receptor inhibitor for patients with hormone-refractory prostate cancer. Clin. Cancer Res., 2001 ; 7 : 800-805.
15. LARA P.N. JR, CHEE K.G., LONGMATE J., RUEL C., MEYERS F.J., GRAY C.R., EDWARDS R.G., GUMERLOCK P.H., TWARDOWSKI P., DOROSHOW J.H., GANDARA D.R. : Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer, 2004 ; 100 : 2125-2131.
16. LEU K.M., THOMAS D.G., BAKER L.H. : Platelet-derived growth factor receptor (PDGF-R) a and b expression in human malignancies. Proc. Am. Soc. Clin. Oncol., 2004 ; 444 : Abstract 1774.
17. LYNCH T.J., BELL D.W., SORDELLA R., GURUBHAGAVATULA S., OKIMOTO R.A., BRANNIGAN B.W., HARRIS P.L., HASERLAT S.M., SUPKO J.G., HALUSKA F.G., LOUIS D.N., CHRISTIANI D.C., SETTLEMAN J., HABER D.A. : Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 2004 ; 350 : 2129-2139.
18. MANDLER R., KOBAYASHI H., HINSON E.R., BRECHBIEL M.W., WALDMANN T.A. : Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity. Cancer Res., 2004 ; 64 : 1460-1467.
19. MATHEW P., THALL P.F., JONES D., PEREZ C., BUCANA C., TRONCOSO P., KIM S.J., FIDLER I.J., LOGOTHETIS C. : Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel : a modular phase I trial in androgen-independent prostate cancer. J. Clin. Oncol., 2004 ; 22 : 3323-3329.
20. MATHEW P., FIDLER I.J., LOGOTHETIS C.J. : Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Semin. Oncol., 2004 ; 31 : 24-29.
21. MELLINGHOFF I.K., TRAN C., SAWYERS C.L. : Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res., 2002 ; 62 : 5254-5259.
22. MORRIS M.J., REUTER V.E., KELLY W.K., SLOVIN S.F., KENNESON K., VERBEL D., OSMAN I., SCHER H.I. : HER-2 profiling and targeting in prostate carcinoma. Cancer, 2002 ; 94 : 980-986.
23. MUNSTER PN, MARCHION DC, BASSO AD, ROSEN N. : Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway. Cancer Res., 2002 ; 62 : 3132-3137.
24. NECKERS L. : Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer. Clin. Cancer Res., 2002 ; 8 : 962-966.
25. PAEZ J.G., JANNE P.A., LEE J.C., TRACY S., GREULICH H., GABRIEL S., HERMAN P., KAYE F.J., LINDEMAN N., BOGGON T.J., NAOKI K., SASAKI H., FUJII Y., ECK M.J., SELLERS W.R., JOHNSON B.E., MEYERSON M. : EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy. Science. 2004 ; 304 : 1497-1500.
26. PAO W., MILLER V., ZAKOWSKI M., DOHERTY J., POLITI K., SARKARIA I., SINGH B., HEELAN R., RUSCH V., FULTON L., MARDIS E., KUPFER D., WILSON R., KRIS M., VARMUS H. : EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA., 2004 ; 101 : 13306-13311.
27. PAULE B., BRION N. : Récepteurs EGF dans les cancers urologiques. Ann. Med. Interne, 2003 ; 154 : 448-456.
28. PAULE B. : Prise en charge des métastases osseuses : les stratégies thérapeutiques en 2003. Prog. Urol., 2003 ; 13 : 36-47.
29. PETRYLAK D.P., TANGEN C.M., HUSSAIN M.H., LARA P.N. JR, JONES J.A., TAPLIN M.E., BURCH P.A., BERRY D., MOINPOUR C., KOHLI M., BENSON M.C., SMALL E.J., RAGHAVAN D., CRAWFORD E.D. : Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med., 2004 ; 351 : 1513-1520.
30. PIETRAS K., RUBIN K., SJOBLOM T., BUCHDUNGER E., SJOQUIST M., HELDIN C.H., OSTMAN A. : Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res., 2002; 62 : 5476-5484.
31. PIETRAS K., STUMM M., HUBERT M., BUCHDUNGER E., RUBIN K., HELDIN C.H., MCSHEEHY P., WARTMANN M., OSTMAN A. : STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin. Cancer Res., 2003 ; 9 : 3779-3787.
32. PIETRAS K., SJOBLOM T., RUBIN K., HELDIN C.H., OSTMAN A. : PDGF receptors as cancer drug targets.Cancer Cell. 2003 ; 3 : 439-443.
33. ROSS J.S., SHEEHAN CE, HAYNER-BUCHAN A.M., AMBROS R.A., KALLAKURY B.V., KAUFMAN R.P. JR, FISHER H.A., RIFKIN M.D., MURACA P.J. : Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer. 1997 ; 79 : 2162-2170.
34. SANCHEZ K.M., SWEENEY C.J., MASS R., KOCH M.O., ECKERT G.J., GEARY W.A., BALDRIDGE L.A., ZHANG S., EBLE J.N., CHENG L. : Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology. Cancer, 2002 ; 95 : 1650-1655.
35. SCHER H.I. : HER2 in prostate cancer - a viable target or innocent bystander ? J. Natl. Cancer Inst., 2000 ; 92 : 1866-1868.
36. SIGNORETTI S., MONTIRONI R., MANOLA J., ALTIMARI A., TAM C., BUBLEY G., BALK S., THOMAS G., KAPLAN I., HLATKY L., HAHNFELDT P., KANTOFF P., LODA M. : Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl. Cancer Inst., 2000 ; 92 : 1918-1925.
37. SMITH M.C., LUKER K.E., GARBOW J.R., PRIOR J.L., JACKSON E., PIWNICA-WORMS D., LUKER G.D. : CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res., 2004 ; 64 : 8604-8612.
38. SOLIT D.B., ZHENG F.F., DROBNJAK M., MUNSTER P.N., HIGGINS B., VERBEL D., HELLER G., TONG W., CORDON-CARDO C., AGUS D.B., SCHER H.I., ROSEN N. : 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res, 2002 ; 8 : 986-993.
39. TAICHMAN R.S., COOPER C., KELLER E.T., PIENTA K.J., TAICHMAN N.S., MCCAULEY L.K. : Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res, 2002 ; 62 : 1832-1837.
40. TANNOCK I.F., DE WIT R., BERRY W.R., HORTI J., PLUZANSKA A., CHI K.N., OUDARD S., THEODORE C., JAMES N.D., TURESSON I., ROSENTHAL M.A., EISENBERGER M.A. : TAX 327 INVESTIGATORS. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med., 2004 ; 351 : 1502-1512.
41. UEHARA H., KIM S.J., KARASHIMA T., SHEPHERD D.L., FAN D., TSAN R., KILLION J.J. LOGOTHETIS C., MATHEW P., FIDLER I.J. : Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J. Natl. Cancer Inst., 2003 ; 95 : 458-470.
42. YEH S., LIN H.K., KANG H.Y., THIN T.H., LIN M.F., CHANG C. : From HER2/Neu signal cascade to androgen receptor and its coactivators : a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. USA., 1999 ; 96 10 : 5458-5463.
43. YU J., USTAC H.C., KIM H.R. : Platelet-derived growth factor signaling and human cancer. J. Biochem. Mol. Biol., 2003 ; 36 : 49-59.